Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8111745 | 0.81 | CA2 (0.36) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL14800271 | 0.79 | KDM4E (0.37) | CA2KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL18978999 | 0.79 | PTPN1 (0.32) | CA2CYP3A4 | |
| SCHEMBL849140 | 0.78 | CA2 (0.73) | CA2KDM4EALDH1A1ALOX15CA12 | |
| SCHEMBL1222790 | 0.78 | CA2 (0.73) | CA2KDM4EALDH1A1ALOX15CA12 | |
| SCHEMBL1416178 | 0.78 | CA2 (0.73) | CA2KDM4EALDH1A1ALOX15CA12 | |
| SCHEMBL18978978 | 0.76 | ADRA1A (0.44) | — | |
| SCHEMBL18979041 | 0.76 | PTPN1 (0.33) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL17100977 | 0.76 | KDM4E (0.34) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1846086 | 0.75 | CYP2D6 (0.38) | CA2APPALDH1A1TSHRCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 251 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | SANOFI (FR) | 2026-03-24 | — | — | US | disclosed |
| EP-4288438-B1 | DERIVATIVES OF IMIDAZO[4,5-D]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-02-18 | — | — | EP | disclosed |
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2025102261-A1 | LIPID COMPOUNDS FOR DELIVERING THERAPEUTIC AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | 尧唐(上海)生物科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-12285490-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240366774-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-11-07 | — | — | US | disclosed |
| WO-2024193525-A1 | LIPID COMPOUND FOR DELIVERING THERAPEUTIC AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 尧唐(上海)生物科技有限公司 | 2024-09-26 | — | — | WO | disclosed |
| WO-2024192906-A1 | LIPID COMPOUND FOR DELIVERING THERAPEUTIC AGENT, PREPARATION METHOD THEREFOR, AND USE THEREOF | 尧唐(上海)生物科技有限公司 | 2024-09-26 | — | — | WO | disclosed |
| WO-2006100631-A1 | HYDROGENATED BENZO (C) THIOPHENE DERIVATIVES AS IMMUNOMODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006010379-A1 | NOVEL THIOPHENE DERIVATIVES AS IMMUNOSUPPRESSIVE AGENTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010544-A2 | 1, 1A, 5, 5A-TETRAHYDRO-3-THIA-CYCLOPROPA’A! PENTALENES: TRICYCLIC THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-02-02 | — | — | WO | disclosed |
| US-20050131016-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1485371-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | AstraZeneca AB (SE) | 2004-12-15 | — | — | EP | disclosed |
| EP-1483270-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | Astrazeneca AB (SE) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074513-A2 | INDOLE AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074532-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS INHIBITORS OF GLYCOGEN PHOSPHORYLASE | ASTRAZENECA AB (SE) | 2003-09-12 | — | — | WO | disclosed |
| WO-1997032879-A1 | 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES | NOVARTIS AG (CH) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366774-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | ASH1L, ASH2L, DOT1L | CA2 4474/4885APP 2575/4885KDM4E 206/4885 |
| US-12583861-B2 | Derivatives of imidazo[4,5-d]pyridazine, their preparation and their therapeutic application | TLR7, TLR8, TLR6 | CA2 940/4885APP 4226/4885KDM4E 2479/4885 |
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | CA2 3826/4885APP 3427/4885KDM4E 3785/4885 |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | PYGL, GYS2, GYS1 | CA2 273/4885APP 2312/4885KDM4E 1809/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | CA2 4683/4885APP 73/4885KDM4E 935/4885 |
| US-20050131016-A1 | Chemical compounds | PYGL, GYS1, CA9 | CA2 129/4885APP 2463/4885KDM4E 1944/4885 |
| US-20250388566-A1 | PROTEIN DEGRADERS AND USES THEREOF | SRR, SRRM2, CRBN | CA2 788/4885APP 1302/4885KDM4E 2825/4885 |
| US-12285490-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | CA2 4474/4885APP 2575/4885KDM4E 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.